CN110250526A - A kind of health food and preparation method thereof with auxiliary lipid-lowering function - Google Patents
A kind of health food and preparation method thereof with auxiliary lipid-lowering function Download PDFInfo
- Publication number
- CN110250526A CN110250526A CN201910603437.7A CN201910603437A CN110250526A CN 110250526 A CN110250526 A CN 110250526A CN 201910603437 A CN201910603437 A CN 201910603437A CN 110250526 A CN110250526 A CN 110250526A
- Authority
- CN
- China
- Prior art keywords
- health food
- fructus lycii
- extract
- black fruit
- fruit fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 20
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 20
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 19
- 229920001202 Inulin Polymers 0.000 claims abstract description 14
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 14
- 229940029339 inulin Drugs 0.000 claims abstract description 14
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 18
- 150000002632 lipids Chemical class 0.000 abstract description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 10
- 102000019280 Pancreatic lipases Human genes 0.000 abstract description 10
- 108050006759 Pancreatic lipases Proteins 0.000 abstract description 10
- 229940116369 pancreatic lipase Drugs 0.000 abstract description 9
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 abstract 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 abstract 1
- 108010055297 Sterol Esterase Proteins 0.000 description 15
- 102000000019 Sterol Esterase Human genes 0.000 description 15
- 241000252212 Danio rerio Species 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 240000008892 Helianthus tuberosus Species 0.000 description 6
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241001092040 Crataegus Species 0.000 description 5
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 5
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 5
- 235000009685 Crataegus X maligna Nutrition 0.000 description 5
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 5
- 235000009486 Crataegus bullatus Nutrition 0.000 description 5
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 5
- 235000009682 Crataegus limnophila Nutrition 0.000 description 5
- 235000004423 Crataegus monogyna Nutrition 0.000 description 5
- 235000002313 Crataegus paludosa Nutrition 0.000 description 5
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108090001060 Lipase Proteins 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940040461 lipase Drugs 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 235000019626 lipase activity Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000169546 Lycium ruthenicum Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- -1 flavone compounds Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000007247 enzymatic mechanism Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007026 Calculus urethral Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000008440 Crataegus cuneata Nutrition 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 235000014283 Crataegus pinnatifida var major Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A kind of health food with auxiliary lipid-lowering function is disclosed in the present invention, is made of the raw material of following mass fraction: 4~10 parts of inulin, 2~5 parts of black fruit fructus lycii leaf extract, 1~3 part of haw thorn extract, 1~4 part of Lotus Leafextract.Health food prepared by the present invention can significantly inhibit the activity of hyperlipidemia related target pancreatic lipase and cholesteryl esterase, blood lipid level be effectively reduced, and natural without side-effects.
Description
Technical field
The present invention relates to field of health care food more particularly to a kind of health foods and its system with auxiliary lipid-lowering function
Preparation Method.
Background technique
Hyperlipidemia refers to TC or TG in blood and its associated lipoprotein level is excessively high or serum high-density LP gallbladder is solid
Alcohol is too low.Hyperlipidemia is related to a variety of diseases such as hypertension, coronary heart disease, cerebral apoplexy, diabetes.It is moved as caused by hyperlipidemia
Pulse atherosclerosis is the main reason for causing the cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction, cerebral hemorrhage, cerebral infarction, and current
Fat-reducing medicament on the market mainly has Statins, fibrates, niacin class etc..Statins are that two phthalein of typical light methylpent is auxiliary
Enzyme reductase inhibitor, it is significant in efficacy but expensive, and there is the potential toxic side effects such as hepatotoxicity wind agitation, muscle poison.Cause
This, the drug for developing natural, nontoxic treatment hyperlipidemia will have important practical significance and potentiality to be exploited.
Summary of the invention
It is an object of the invention to solve existing fat-reducing medicament during treating hyperlipidemia, the secondary work of poison is generated to human body
With the problem of, provide a kind of health food and preparation method thereof with auxiliary lipid-lowering function, which can be effective
Assist reducing blood lipid and Pure natural nontoxic side effect.
In order to solve the above technical problems, The technical solution adopted by the invention is as follows: a kind of with auxiliary lipid-lowering function
Health food is made of the raw material of following mass fraction: 4~10 parts of inulin, 2~5 parts of black fruit fructus lycii leaf extract, hawthorn are extracted
1~3 part of object, 1~4 part of Lotus Leafextract.
A kind of preparation method of the health food with auxiliary lipid-lowering function, comprising the following steps:
A, inulin, black fruit fructus lycii leaf extract, haw thorn extract and Lotus Leafextract are weighed according to quality proportioning spare；
B, it is passed through after being uniformly mixed load weighted inulin, black fruit fructus lycii leaf extract, haw thorn extract and Lotus Leafextract
It pulverizes；
C, the mixture after pulverizing in step B is mixed with microcrystalline cellulose according to the mass ratio of 2~5:4~10
Even, health food is made in tabletting.
Jerusalem artichoke (Helianthus tuberosus) is commonly called as potato head, Jerusalem artichoke.Jerusalem artichoke usually yields positive results in the fall,
Small disc floret with yellow, this flower-shape such as chrysanthemum, the stem tuber grown in king's earth are fine rich in carbohydrate, a small amount of protein, diet
Dimension, pectin, organic acid and several mineral materials etc..Containing jerusalem artichoke water-soluble dietary fiber in fresh jerusalem artichoke is a kind of dietary nutrient,
There is significant healthcare function to human body.Modern pharmacology research discovery, inulin has reducing blood lipid, hypoglycemic, and treatment constipation etc. is more
Kind effect.
Black fruit fructus lycii (Lycium ruthenicum Murr.) is Solanaceae Lycium, is commonly called as lycium ruthenicum, is China west
Northern region-by-region common wild bush is circle after berry fruit is mature, darkly purple.Tibetan medicine black fruit fructus lycii is referred to as " other
Ma ", the Four-Volume Medical Code are recorded, and Tibetan medicine is used as medicine with its ripening fruits, the diseases such as treatment cardiopyretic disease, heart disease, irregular menstruation, menopause
Disease, " Uygur medicine will " are recorded, and lycium ruthenicum fruit and root skin can treat the diseases such as urethral calculus, tinea scabies, gingiva bleeding gingival hemorrhage, it is civil then
As strengthening by means of tonics, improving eyesight and depressor.Black fruit fructus lycii leaf is rich in a variety of flavone compounds, and pharmacological research is found to have drop
The effect of blood lipid.
Hawthorn be rosaceous plant large-fruited Chinese hawthorn (Crataegus pinnatifida Bge.Var.major N.E.Br.) or
The dry mature fruit of hawthorn (Crataegus pinnatifida Bge.), dual-purpose of drug and food, is used to spleen benefiting and stimulating the appetite, disappears from ancient times
Foodization is stagnant etc..Modern pharmacology research proves, hawthorn has effect for reducing blood fat, can be substantially reduced total cholesterol, triglycerides, low
Density lipoprotein-cholesterol is horizontal, increasing high density lipoprotein cholesterol levels, can be used to prevent and treat hyperlipidemia, and do not have
Toxic side effect.
Lotus leaf (Nelumbinis Folium) belongs to the blade of nymphaeaceae plant lotus (Nelumbo nucifera Gaertn),
It is distributed in China's most area, main product is in Hunan, Fujian, Jiangsu, Zhejiang, Jiangxi and other places.Lotus leaf is mild-natured, bitter, return liver,
Spleen, stomach meridian have clearing away summer-heat and eliminating dampness, sending up the lucid yang, cooling blood and hemostasis and other effects.Record according to Compendium of Material Medica: lotus leaf takes it, makes us thin
Bad, hair tonic vigour, benefit helps taste.Modern research shows that alkaloid and flavones ingredient in lotus leaf have inhibit pancreatic lipase,
The effects of reducing blood lipid, anti-aging.
For pancreatic lipase in three ester hydrolysis of gastrointestinal tract catalyzing glycerol, triglycerides is the energy source of high calorie, is inhibited sweet
The absorption of oily three esters can the diseases such as pre- preventing obesity and hyperlipidemia, inhibit pancreatic lipase activity be pre- preventing obesity main road
Diameter.Cholesterol esterase is widely studied as the target of control cholesterol levels.Cholesterol esterase is in hydrolysis diet cholesterol
It plays an important role in terms of ester and transhipment free cholesterol to enterocyte.The present invention is by inulin, black fruit fructus lycii leaf extract, hawthorn
Four kinds of components of extract and Lotus Leafextract carry out compatibility, and the health food of preparation can effectively inhibit cholesterol esterase and pancreas rouge
The activity of fat enzyme, to have the function that reducing blood lipid, and natural without any side effects.
The utility model has the advantages that health food prepared by the present invention can significantly inhibit hyperlipidemia related target pancreas possessed by of the invention
Blood lipid level is effectively reduced in the activity of lipase and cholesterol esterase, and natural without side-effects.
Detailed description of the invention
Fig. 1 is the effect picture of the complex tablet reducing blood lipid prepared in zebra fish zoopery according to embodiment 1.
Fig. 2 is to inhibit pancreatic lipase activity figure according to complex tablet prepared by embodiment 1 in pancreatic lipase activity experiment.
Fig. 3 is to inhibit cholesterol esterase activity according to complex tablet prepared by embodiment 1 in cholesterol esterase activity experiment
Figure.
Fig. 4 is to inhibit cholesteryl ester enzyme mechanism according to complex tablet prepared by embodiment 1 in the experiment of cholesteryl ester enzyme mechanism
Figure.
Fig. 5 is to inhibit cholesterol esterase power according to complex tablet prepared by embodiment 1 in cholesterol esterase dynamic experiment
Figure.
Specific embodiment
The present invention is further illustrated in the following with reference to the drawings and specific embodiments.
Embodiment 1
It weighs 40g inulin, 20g black fruit fructus lycii leaf extract, 10g haw thorn extract and 10g Lotus Leafextract and mixes, pass through
It is uniformly mixed after ultramicro grinding with 160g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
Embodiment 2
It weighs 100g inulin, 50g black fruit fructus lycii leaf extract, 30g haw thorn extract and 40g Lotus Leafextract and mixes,
It is uniformly mixed after pulverizing with 440g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
Embodiment 3
It weighs 50g inulin, 30g black fruit fructus lycii leaf extract, 20g haw thorn extract and 20g Lotus Leafextract and mixes, pass through
It is uniformly mixed after ultramicro grinding with 200g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
Embodiment 4
It weighs 60g inulin, 40g black fruit fructus lycii leaf extract, 30g haw thorn extract and 30g Lotus Leafextract and mixes, pass through
It is uniformly mixed after ultramicro grinding with 240g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
Embodiment 5
It weighs 70g inulin, 50g black fruit fructus lycii leaf extract, 20g haw thorn extract and 40g Lotus Leafextract and mixes, pass through
It is uniformly mixed after ultramicro grinding with 315g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
Embodiment 6
It weighs 70g inulin, 30g black fruit fructus lycii leaf extract, 20g haw thorn extract and 30g Lotus Leafextract and mixes, pass through
It is uniformly mixed after ultramicro grinding with 400g microcrystalline cellulose, then health care product complex tablet is made in tabletting.
The zoopery of health care product complex tablet auxiliary reducing blood lipid
Experimental animal: zebra fish.
Experimental material: test medicine: health care product complex tablet prepared by embodiment 1；Methylcellulose (Sigma,
China)；Isopropanol (examination of Shanghai Shanghai, Chinese Shanghai, lot number 80109218)；Dimethyl sulfoxide/DMSO (Sigma-
Aldrich, Chinese Shanghai, lot number BCBT0803).
Laboratory apparatus: Desk type constant-temperatureoscillator oscillator (Chinese Shanghai Jing Hong experimental facilities Co., Ltd THZ-312), microplate reader
(German Siemens Healthineers)；High speed freezing centrifuge (German SIGMA 3-18K type), disecting microscope (SZX7,
OLYMPUS, Japan)；The camera (VertA1) being connected with microscope；Power focus continuous zoom fluorescence microscope (AZ100,
Nikon company)；Heartbeat blood flow analysis system (Zebralab3.3 (PB2084C))；Precision electronic balance (CP214, OHAUS,
America)；96 orifice plates and six orifice plates (Fisher Scientific, China).
Experimental method:
1, it establishes zebra fish high blood lipid model: randomly selecting 5 days (5dpf) melanin allelic variants half of after fertilization
Transparent Albino strain zebra fish establishes high blood lipid model in beaker, with yolk powder feeding zebra fish.
2, experimental group: randomly selecting the zebra fish of 90 tail high blood lipid models in six orifice plates, and every hole handles 30 tail zebra fish,
Health care product complex tablet is added into every hole and with DMSO hydrotropy, concentration 0.1%.Positive controls: 90 tails are randomly selected
For the zebra fish of high blood lipid model in six orifice plates, every hole handles 30 tail zebra fish, and drug Lovastatin is added into every hole, dense
Degree is 0.2 μM.Negative control group: randomly selecting the zebra fish of 90 tail high blood lipid models in six orifice plates, every 30 tail zebra fish of hole.
After experimental group, positive controls and negative control group are handled 48h, dyed with oil red O, each group of difference is random after dyeing
It chooses 10 tail zebra fish to take pictures under a dissecting microscope and acquire data, analysis statistics zebra fish tail veins blood lipid optical density is total
With according to the evaluating combined tablet effect for reducing blood fat of the results of statistical analysis of optical density summation.Fig. 1 and the display of table 1, complex tablet
The zebra fish hyperlipidemia induced yolk powder has the function of significant reducing blood lipid.
1 analysis of experimental results table of table
3, pancreatic lipase activity is tested: by the way that lipase is dissolved in system in 100mM Tris-HCl buffer (pH8.0)
Standby pancreatic lipase solution (2.5mg/ml), the buffer include 0.1% gum arabic and 0.2% NaTDC.It will be upper
Lipase solution is stated with 6,000rpm centrifugation 15 minutes to remove insoluble component.4-NPP is dissolved in isopropanol, is then used
Distilled water is diluted to required concentration.The final isopropyl alcohol concentration in solution is tested less than 1.0%.By the complex tablet of various concentration
(1.28,2.56,4.80,6.40,9.60 and 12.80mg/mL) and 80 μ L pancreatic lipases are added in 96 hole microtest plates simultaneously
It is incubated 10 minutes at 37 DEG C.Then the 4-NPP (1.0mM) of 80 μ L is added in said mixture to start to react.By 96 orifice plates
It is incubated again at 37 DEG C 30 minutes, then using microplate reader (Siemens Healthineers, Germany) measurement reaction mixing
Absorbance of the object at 405nm.Each measurement is triplicate to be carried out.Calculate suppression percentage and IC50Value, is shown in Fig. 2.Fig. 2 shows,
Complex tablet is to pancreatic lipase inhibitory activity as oil concentration is in dose dependent increase, IC50Value is 12.38 ± 0.07mg/mL.
4, cholesterol lipase active is tested: by the way that cholesterol esterase (CEase) is dissolved in 0.1M sodium phosphate buffer
2 μ g/mL CEase solution (0.03U/mL) are prepared in (pH 7.04), the buffer includes 0.1M NaCl.The substrate of enzyme
PNPB is dissolved in acetonitrile, tests the final acetonitrile concentration of solution less than 2.0%.Firstly, by the black fruit fructus lycii seed of various concentration
Oil and CEase be added 96 hole microtest plates in and 37 DEG C preincubate 5 minutes.Then, pNPB (0.2mM) is added above-mentioned mixed
It closes in object to start to react, and measures the absorbance of reaction mixture at 405nm.Each experiment is triplicate to be carried out.It calculates
Suppression percentage and IC50Value, is shown in Fig. 3.Complex tablet has dose-dependent inhibition effect to CEase, has stronger effective
Inhibiting effect, IC50Value is 2.63 ± 0.13mg/mL.In addition, the cholesterol esterase of Fig. 4 and Fig. 5 inhibits research and dynamic analysis
Show that complex tablet belongs to the Noncompetition inhibition to reversible inhibition to the suppressor mode of CEase.
The description and the appended drawings of the invention be considered as it is illustrative and not restrictive, on the basis of the present invention, ability
According to disclosed technology contents, some of technical characteristics can be made field technique personnel by not needing creative labor
Some replacements and deformation, are within the scope of the invention.
Claims (2)
1. a kind of health food with auxiliary lipid-lowering function, which is characterized in that be made of the raw material of following mass fraction: chrysanthemum
4~10 parts of powder, 2~5 parts of black fruit fructus lycii leaf extract, 1~3 part of haw thorn extract, 1~4 part of Lotus Leafextract.
2. a kind of preparation method of health food with auxiliary lipid-lowering function according to claim 1, feature exist
In, comprising the following steps:
A, inulin, black fruit fructus lycii leaf extract, haw thorn extract and Lotus Leafextract are weighed according to quality proportioning spare；
B, through ultra micro after load weighted inulin, black fruit fructus lycii leaf extract, haw thorn extract and Lotus Leafextract being uniformly mixed
It crushes；
C, the mixture after pulverizing in step B is uniformly mixed with microcrystalline cellulose according to the mass ratio of 2~5:4~10,
Health food is made in tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910603437.7A CN110250526A (en) | 2019-07-05 | 2019-07-05 | A kind of health food and preparation method thereof with auxiliary lipid-lowering function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910603437.7A CN110250526A (en) | 2019-07-05 | 2019-07-05 | A kind of health food and preparation method thereof with auxiliary lipid-lowering function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110250526A true CN110250526A (en) | 2019-09-20 |
Family
ID=67924607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910603437.7A Pending CN110250526A (en) | 2019-07-05 | 2019-07-05 | A kind of health food and preparation method thereof with auxiliary lipid-lowering function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110250526A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112147288A (en) * | 2020-08-31 | 2020-12-29 | 南京新环检测科技有限公司 | Method for evaluating weight-losing function of health food |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005115427A1 (en) * | 2004-05-31 | 2005-12-08 | Purimed Co., Ltd. | Herbal medicine composition for suppression of obesity and preparation method thereof |
| CN102028286A (en) * | 2009-09-28 | 2011-04-27 | 董丙华 | Lotus leaf weight-losing heath drink |
| CN102526339A (en) * | 2011-12-05 | 2012-07-04 | 宁波海逸生物科技有限公司 | Formulation of healthcare medicine for regulating blood lipid and enhancing immunity |
| CN102836282A (en) * | 2012-09-17 | 2012-12-26 | 青海红鼎生物工程有限公司 | Application of folium lycii total flavone extract |
| CN103768540A (en) * | 2014-02-25 | 2014-05-07 | 刘洪军 | Traditional Chinese medicinal grains for reducing blood fat and preparation method of traditional Chinese medicinal grains |
| CN107822128A (en) * | 2017-11-08 | 2018-03-23 | 兰州大学 | A kind of hawthorn inulin chewable tablet and its compound method |
-
2019
- 2019-07-05 CN CN201910603437.7A patent/CN110250526A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005115427A1 (en) * | 2004-05-31 | 2005-12-08 | Purimed Co., Ltd. | Herbal medicine composition for suppression of obesity and preparation method thereof |
| CN102028286A (en) * | 2009-09-28 | 2011-04-27 | 董丙华 | Lotus leaf weight-losing heath drink |
| CN102526339A (en) * | 2011-12-05 | 2012-07-04 | 宁波海逸生物科技有限公司 | Formulation of healthcare medicine for regulating blood lipid and enhancing immunity |
| CN102836282A (en) * | 2012-09-17 | 2012-12-26 | 青海红鼎生物工程有限公司 | Application of folium lycii total flavone extract |
| CN103768540A (en) * | 2014-02-25 | 2014-05-07 | 刘洪军 | Traditional Chinese medicinal grains for reducing blood fat and preparation method of traditional Chinese medicinal grains |
| CN107822128A (en) * | 2017-11-08 | 2018-03-23 | 兰州大学 | A kind of hawthorn inulin chewable tablet and its compound method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112147288A (en) * | 2020-08-31 | 2020-12-29 | 南京新环检测科技有限公司 | Method for evaluating weight-losing function of health food |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Bioactive compounds from marine macroalgae and their hypoglycemic benefits | |
| Ibrahim et al. | Butanol fraction of Parkia biglobosa (Jacq.) G. Don leaves enhance pancreatic β-cell functions, stimulates insulin secretion and ameliorates other type 2 diabetes-associated complications in rats | |
| CN106794214A (en) | The composition of the mixture of contained molecule in mixture containing plant extracts or the plant, and for controlling the purposes of carbohydrate and/or lipid-metabolism | |
| CN105394748A (en) | Method and composition for nutritionally improving glucose control and insulin action | |
| Hasona et al. | Ameliorative properties of Iranian Trigonella foenum-graecum L. seeds and Punica granatum L. peel extracts in streptozotocin-induced experimental diabetic guinea pigs | |
| Yakubu et al. | Increased liver alkaline phosphatase and aminotransferase activities following administration of ethanolic extract of Khaya senegalensis stem bark to rats | |
| CN101836725B (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| AU2006224909A1 (en) | Medicament consisting of plant extracts as a lipase inhibitor | |
| CN107949394A (en) | It is used to prevent or treats metabolic syndrome or for oxidation resistant composition comprising black soya bean leaf extract and from its separated flavonol glycosides is as active component | |
| Mani et al. | Memory-enhancing activity of Coriandrum sativum in rats | |
| US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
| CN114632101A (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof | |
| CN110250526A (en) | A kind of health food and preparation method thereof with auxiliary lipid-lowering function | |
| CN109966373A (en) | A kind of application of black fruit fructus lycii seed oil extract in blood lipid-lowering medicine | |
| WO2014197861A1 (en) | Synergistic formulation of plant extracts for hepatic and adrenal disorders | |
| CN102596214B (en) | Composition for alleviating fatty liver | |
| EP3041487B1 (en) | Use of propolis against obesity-related pathologies | |
| CN103860706B (en) | A kind of pure Chinese medicine health preparation with protection alcoholic liver injury function | |
| CN101336705B (en) | Health food and its preparation method | |
| JP2009203209A (en) | Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia | |
| Peiris et al. | A Comprehensive Review of Salacia reticulata: Botanical, Ethnomedicinal, Phytochemical, and Pharmacological Insights | |
| US9480724B2 (en) | Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, and leptin levels and increasing adiponectin levels | |
| CN107028164A (en) | A kind of liver protecting health food and preparation method thereof | |
| US8273388B2 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome | |
| CN107898779A (en) | Homo-orientin is being prepared and the purposes in insulin resistance relevant disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190920 |